A Pilot Study Evaluating the Impact of a Prebiotic Soda on Gastrointestinal Symptoms in Users of GLP-1 Agonists

The primary aim of this study is to evaluate the effects of including a daily prebioticsoda (i.e., OLIPOP) over a 4‐week period on gastrointestinal (GI) symptoms in adults whorecently initiated GLP‐1 receptor agonist (GLP‐1 RA).The study design is exploratory in nature and is set up as a real‐world at‐home,randomized two‐arm study. Participants (n=80) will have initiated GLP‐1 RA therapy forweight management at least 1 week but no greater than 4 weeks prior to study enrollmentand have at least one reported GI symptom at enrollment. Participants will be randomizedto either a control group (continuing to drink their usual fluid intake) or a behavioralintervention group (OLIPOP prebiotic soda,1 can (12 fl oz., 6 g dietary fiber)/day, withthe option to consume 2 cans (24 fl oz., 12 g dietary fiber)/day, if desired).Secondary outcomes will include evaluating the effects of prebiotic soda consumption onadditional markers of digestive health support (i.e., bowel frequency and stoolconsistency), health‐related quality of life, body weight and BMI, habitual dietaryintake, appetite, GI symptom rescue medication usage, safety profile (AE/SAE) andparticipant experience and satisfaction.